尽管市场走势疲软,但ADC(抗体偶联药物)龙头企业映恩生物(09606.HK)上市首日仍然大涨。 4月15日,映恩生物(09606.HK)在港交所主板挂牌上市,当天报收于205港元,首日涨幅超过116%。 业内人士认为,距离港交所2018年在新的《主板上市规则》中新增第18A章,允许未盈利、无收入的生物科技公司上市(下称“18A公司”)已有7年,部分头部公司凭借大热单品或商务拓展(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.